Ozempic Cost in North Carolina (2026): Cash Price, Insurance, and Compounded Options

What Ozempic Costs Without Insurance in North Carolina

The retail cash price for brand-name Ozempic at North Carolina pharmacies is $998 per month in 2026, matching Novo Nordisk's national list price. This applies to all pen strengths (0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg), as each box contains four weekly doses.

That figure is consistent across major NC pharmacy chains. CVS, Walgreens, and Walmart locations in Charlotte, Raleigh, Durham, and Greensboro all list Ozempic within a few dollars of $998 per fill. Independent pharmacies occasionally offer modest discounts, but rarely drop below $950.

The price has not changed meaningfully since Novo Nordisk set it. According to an Institute for Clinical and Economic Review (ICER) analysis, the net price after rebates paid to insurers and pharmacy benefit managers is substantially lower than list, but cash-pay patients see none of that discount at the counter [1]. A 2022 Senate Finance Committee report documented that Novo Nordisk's list prices for GLP-1 receptor agonists exceeded the estimated cost-effective threshold by a wide margin [2].

Price varies by dose only if a physician prescribes the lower-dose pen for a patient still in the titration phase. A single Ozempic pen delivering four 0.25 mg doses costs the same as one delivering four 2.0 mg doses. The difference is how many pens ship per box. Patients on the 2.0 mg maintenance dose use one pen per month; patients on 0.5 mg also use one pen per month but from a different pen concentration.

For patients paying cash, the single most effective cost-reduction strategy is the Novo Nordisk savings card, discussed below.

North Carolina Insurance Coverage for Ozempic

Most commercial health insurers in North Carolina cover Ozempic for type 2 diabetes, though nearly all require prior authorization and step therapy. The prior authorization process typically requires documented A1C of 7.0% or above and evidence that metformin was tried first or is contraindicated.

Blue Cross Blue Shield of North Carolina (Blue Cross NC), the state's largest insurer with over 4.2 million members, lists Ozempic on its preferred brand formulary for type 2 diabetes [3]. Copays for preferred brands on BCBSNC plans range from $35 to $75 per month depending on the specific plan tier. United Healthcare and Aetna plans sold on the North Carolina ACA marketplace similarly cover Ozempic for diabetes, though formulary placement and copay amounts vary by metal tier.

Off-label coverage for weight loss is a different story. Few NC commercial plans cover Ozempic specifically for obesity. Some self-insured employer plans make exceptions, but the standard commercial formulary restricts Ozempic to its FDA-approved indication of type 2 diabetes [4]. Patients seeking GLP-1 therapy for weight management alone may have better insurance luck with Wegovy (semaglutide 2.4 mg), which carries an FDA-approved obesity indication.

Cigna and UnitedHealthcare have expanded anti-obesity medication coverage in select employer-sponsored plans nationally, but coverage depends entirely on the employer's benefit design. NC residents should call the number on the back of their insurance card and ask specifically whether their plan covers GLP-1 receptor agonists for obesity, using the ICD-10 code E66.01.

North Carolina Medicaid and Ozempic

North Carolina Medicaid covers Ozempic for type 2 diabetes only. It does not cover the drug for weight loss. This is a firm restriction that applies to both fee-for-service Medicaid and the state's Medicaid managed care plans (operated by WellCare, Healthy Blue, UnitedHealthcare Community Plan, and AmeriHealth Caritas).

North Carolina completed Medicaid expansion in December 2023, adding approximately 600,000 new enrollees [5]. These expansion enrollees have the same pharmaceutical benefit structure as existing Medicaid beneficiaries, meaning Ozempic access requires a confirmed type 2 diabetes diagnosis.

The NC Division of Health Benefits Preferred Drug List (PDL) classifies GLP-1 receptor agonists as a prior-authorization drug class. To obtain approval, the prescribing clinician must submit documentation of A1C at or above 7.0%, failure or intolerance of metformin, and a diagnosis of type 2 diabetes mellitus. Weight-only diagnoses (E66.01, E66.09) will result in denial.

For Medicaid enrollees with type 2 diabetes who receive approval, the out-of-pocket cost is $0 to $3 per fill depending on income level. That represents a dramatic contrast with the $998 cash price.

How the Novo Nordisk Savings Card Works in North Carolina

The Novo Nordisk Ozempic Savings Card can reduce out-of-pocket costs to as low as $25 per month for commercially insured patients. The card covers up to $150 per 30-day supply for 24 months. It works at any NC pharmacy that accepts manufacturer copay cards.

Eligibility requirements are straightforward but exclusionary for some patients. The card is available to patients with commercial insurance only. Medicare, Medicaid, Tricare, and other government-funded insurance beneficiaries are ineligible by federal anti-kickback statute [6]. Cash-pay patients without any insurance are also technically ineligible for the standard savings card, though Novo Nordisk has periodically offered separate patient assistance programs for uninsured individuals.

To activate the card, patients visit the Ozempic manufacturer website, complete an enrollment form, and receive a digital or physical card with a BIN and PCN number. The pharmacist processes it as a secondary claim after running the primary insurance. If the primary insurance covers Ozempic with a $75 copay, for example, the savings card reduces the patient's responsibility to $25. If the copay is already below $25, the card provides no additional benefit.

One NC-specific consideration: the savings card does not work at pharmacies participating in the federal 340B drug pricing program. Several Federally Qualified Health Centers (FQHCs) and hospital outpatient pharmacies in North Carolina are 340B entities, and patients filling prescriptions at these locations may need to use a retail pharmacy instead to apply the card.

Compounded Semaglutide in North Carolina: Legality and Pricing

Compounded semaglutide is legal in North Carolina when dispensed by a state-licensed 503A compounding pharmacy with a valid patient-specific prescription. The typical price is approximately $199 per month, representing an 80% reduction from brand-name Ozempic.

The regulatory framework rests on Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding pharmacies to prepare patient-specific medications when a prescriber determines the commercially available product is not appropriate for a given patient [7]. North Carolina's Board of Pharmacy licenses and inspects 503A compounding facilities operating within the state.

The FDA's stance on compounded semaglutide shifted in 2024 when the agency removed semaglutide from its drug shortage list. Following that change, the FDA issued warning letters to compounders who continued producing semaglutide products, arguing the shortage exception no longer applied. Legal challenges followed. As of early 2026, litigation between compounding pharmacy trade groups and the FDA remains active, and compounded semaglutide continues to be dispensed in states, including North Carolina, where 503A pharmacies operate under state licensure [8].

Patients considering compounded semaglutide should verify three things. First, the pharmacy must hold a valid North Carolina Board of Pharmacy compounding license. Second, the product should be semaglutide base or semaglutide sodium, not a semaglutide "analog" or "peptide blend." Third, the pharmacy should provide a certificate of analysis (COA) from a third-party testing lab confirming purity and potency. The North Carolina Board of Pharmacy maintains a public license lookup tool for verification.

Dr. Caroline Apovian, a co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, has stated: "Patients using compounded GLP-1 medications need to understand that these products have not undergone the same rigorous clinical testing as FDA-approved versions. Quality can vary between pharmacies, and patients should insist on third-party testing documentation."

Compounded semaglutide is administered as a subcutaneous injection, the same route as Ozempic. Dosing protocols typically mirror the FDA-approved titration schedule: 0.25 mg weekly for four weeks, then 0.5 mg weekly, with increases to 1.0 mg or higher based on clinical response and tolerability.

Ozempic via Telehealth in North Carolina

Telehealth prescribing of Ozempic is legal in North Carolina, and multiple platforms serve the state. NC law permits clinicians to prescribe controlled and non-controlled medications via synchronous audio-video visits, and semaglutide is not a controlled substance.

The North Carolina Medical Board requires that telehealth prescribers establish a valid provider-patient relationship before issuing a prescription. For semaglutide, this means a video consultation that includes medical history review, current medication reconciliation, and discussion of risks and benefits [9]. Audio-only visits may not meet the standard for initial prescriptions of injectable medications in North Carolina, though follow-up visits can use audio-only modalities.

Telehealth platforms operating in North Carolina typically charge $99 to $199 for an initial consultation, with monthly follow-ups ranging from $49 to $99. These fees cover the clinical visit only. The medication is billed separately, either through the patient's insurance or as a cash-pay transaction at a partner pharmacy.

SUSTAIN-7, a head-to-head randomized trial comparing semaglutide with dulaglutide in 1,201 adults with type 2 diabetes, found that semaglutide 1.0 mg produced a mean A1C reduction of 1.8% at 40 weeks, compared with 1.4% for dulaglutide 1.5 mg (P<0.0001) [10]. Weight loss was 6.5 kg with semaglutide 1.0 mg versus 3.0 kg with dulaglutide 1.5 mg. These data support why clinicians prescribing via telehealth in North Carolina frequently select semaglutide over older GLP-1 agents.

For NC patients using telehealth, the prescription is sent electronically to a pharmacy of the patient's choosing. Patients can select a local NC retail pharmacy, a mail-order pharmacy, or a compounding pharmacy depending on their cost and product preferences.

Comparing Ozempic Cost Options for NC Residents

A side-by-side comparison helps NC patients evaluate their realistic options:

Brand Ozempic with commercial insurance: $25 to $75 per month after copay, potentially $25 with the Novo Nordisk savings card. Requires prior authorization for type 2 diabetes. Off-label weight-loss coverage is rare.

Brand Ozempic cash pay: $998 per month. No prior authorization needed. The savings card does not apply to uninsured patients in most cases.

Brand Ozempic with NC Medicaid: $0 to $3 per fill, but only for type 2 diabetes. Denied for weight-loss-only indications.

Compounded semaglutide: approximately $199 per month through a licensed NC 503A pharmacy. No insurance billing in most cases. Requires a valid prescription.

Wegovy (semaglutide 2.4 mg for obesity): $1,349 per month list price. Covered by some commercial plans for BMI of 30 or above (or 27 or above with a comorbidity). Not covered by NC Medicaid for weight loss.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for adults with BMI of 30 kg/m² or above, or BMI of 27 kg/m² or above with at least one weight-related comorbidity [11]. For NC patients who meet these criteria but lack insurance coverage, compounded semaglutide represents the most affordable injectable GLP-1 option.

NC Pharmacy Discount Programs and Patient Assistance

Beyond the Novo Nordisk savings card, several discount pathways exist for North Carolina residents.

GoodRx and RxSaver coupons can reduce the Ozempic cash price at NC pharmacies to between $850 and $935, depending on the pharmacy. This represents a modest savings of $60 to $150 compared with list price, but still leaves the cost near $900 monthly.

The Novo Nordisk Patient Assistance Program (PAP) provides Ozempic at no cost to uninsured patients with household income below 400% of the federal poverty level. For a single individual in 2026, that threshold is approximately $62,400. Approval requires income documentation and a valid prescription from a licensed clinician [12].

North Carolina's 340B-eligible health centers, including Community Care of the Lower Cape Fear, Piedmont Health Services, and Lincoln Community Health Center, may offer discounted pricing for qualifying patients. The 340B program requires pharmaceutical manufacturers to sell outpatient drugs at significantly reduced prices to eligible healthcare organizations. Patients receiving care at these centers should ask whether 340B pricing applies to their semaglutide prescription.

Mark McClellan, MD, PhD, former FDA Commissioner and current director of the Duke-Margolis Institute for Health Policy, noted in a 2024 policy brief: "State-level variation in GLP-1 access is creating a two-tier system where patients with generous employer coverage get treatment easily, while uninsured and Medicaid populations face significant barriers."

What to Expect When Starting Ozempic in North Carolina

The standard Ozempic titration schedule begins at 0.25 mg weekly for four weeks, increases to 0.5 mg weekly for four weeks, then to 1.0 mg weekly. The maximum approved dose is 2.0 mg weekly [13]. Most NC prescribers follow this titration regardless of whether the patient fills at a retail or compounding pharmacy.

Common side effects reported in the SUSTAIN clinical trial program include nausea (15.8% to 20.3%), vomiting (5.0% to 9.2%), diarrhea (8.5% to 8.8%), and constipation (3.1% to 5.0%) at the 1.0 mg dose [10]. These gastrointestinal effects are typically most pronounced during the first four to eight weeks and diminish with continued use.

The Ozempic prescribing information carries a boxed warning regarding thyroid C-cell tumors observed in rodents [13]. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

NC patients starting Ozempic should have baseline labs drawn including A1C, fasting glucose, a comprehensive metabolic panel, and lipid panel. Follow-up labs at 12 weeks allow the prescribing clinician to assess glycemic response and adjust the dose or add-on therapies accordingly.